Medtronic PLC’s bombshell news, the disappointing clinical results for its Symplicity renal denervation product, left a smoking crater on the medtech landscape during the JP Morgan Healthcare Conference (JPM) in San Francisco, held earlier this month. Large-cap executives and venture capitalists who saw great promise in the new therapeutic approach (see Also see "Renal Denervation Sparks Device Market Gold Rush" - Medtech Insight, 25 May, 2012.) spent time trying to gauge the size and scope of the damage on the medtech industry and their own particular portfolios.
The SYMPLICITY HTN-3 trial followed two successful trials that demonstrated efficacy for the approach of ablating nerves within the renal artery to lower blood pressure in chronic hypertension patients who...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?